However... you can't use that antibody directly in humans, since it is a mouse antibody, which the human immune system will recognize as foreign. So, even if this treatment were to work, it is necessary is to first "humanize" the antibody so it won't be rejected, and then you can see what effect you get in a clinical trial. I imagine this is what the $20mil funding is for.
That is a mouse antibody (viz, Isotype: Mouse IgG1, κ) targeted to the human CD47 protein, the same problem exists as for the one mentioned in the above article.
This is the original article: http://www.pnas.org/content/109/17/6662
You can actually get the antibody yourself, FTA: "The anti-hCD47 (B6H12) hybridoma was obtained from the ATCC" [http://www.lgcstandards-atcc.org/Products/All/HB-9771.aspx]
Purifying it is easy, if you have a lab.
However... you can't use that antibody directly in humans, since it is a mouse antibody, which the human immune system will recognize as foreign. So, even if this treatment were to work, it is necessary is to first "humanize" the antibody so it won't be rejected, and then you can see what effect you get in a clinical trial. I imagine this is what the $20mil funding is for.
You can find clinical trials for new drugs here:
http://clinicaltrials.gov/